Life Science Investing Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Life Science Investing Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Life Science Investing SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Life Science Investing Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
Life Science Investing Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Life Science Investing Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Life Science Investing Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Nextech3D.ai Announces CEO Evan Gappelberg Acquires 550,000 Shares of Company Stock In Open Market Buys
